Related Experiment Video
Updated: Jun 9, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Cost-effectiveness of strengthening blood pressure classification in South Korea: comparing the 2017 ACC/AHA and KSH
KyungYi Kim1, Min Ji Hong2, Bomgyeol Kim3
1Department of Healthcare Management, Graduate School of Public Health, Yonsei University, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Insights
Adopting the 2017 ACC/AHA hypertension guidelines in South Korea is cost-effective, potentially reducing cardiovascular disease (CVD) events. This approach offers significant public health benefits and supports policy decisions on blood pressure targets.
Area of Science:
- Health Economics
- Public Health Policy
- Cardiovascular Disease Prevention
Background:
- Hypertension significantly increases cardiovascular disease (CVD) risk, with rising mortality rates.
- South Korea currently follows the Korean Society of Hypertension (KSH) guideline (140/90 mmHg).
- The 2017 ACC/AHA guidelines recommend a lower threshold (130/80 mmHg).
Purpose of the Study:
- To evaluate the cost-effectiveness of adopting the 2017 ACC/AHA hypertension guidelines in South Korea.
- To estimate the impact of earlier blood pressure treatment on CVD risk reduction.
- To inform policy decisions regarding hypertension management guidelines.
Main Methods:
- A 10-year Markov state-transition simulation model was employed.
- Quality-adjusted life years (QALYs) were used to measure effectiveness.
- Analyses compared cohorts of 10,000 individuals across age groups (20s-80s) from a healthcare system perspective.
Main Results:
- The base-case incremental cost-effectiveness ratio (ICER) was KRW 1,328,395/QALY gained.
- ICERs varied by age, with younger individuals showing negative ICERs (cost-saving) and older individuals showing higher positive ICERs.
- All scenarios remained below the willingness-to-pay threshold, with a 98.0% probability of cost-effectiveness.
Conclusions:
- Adopting the 2017 ACC/AHA guidelines is projected to be cost-effective across all South Korean age groups.
- Implementing these guidelines may lead to earlier hypertension treatment and reduced CVD incidence.
- Findings provide crucial economic data for policymakers considering guideline revisions.
Background:
Hypertension is a significant risk factor for cardiovascular disease (CVD), with hypertension-related deaths increasing annually. While South Korea uses the Korean Society of Hypertension (KSH) guideline of 140/90 mmHg, the American College of Cardiology (ACC) and American Heart Association (AHA) updated their guidelines in 2017 to 130/80 mmHg. This study evaluates the cost-effectiveness of transitioning to the 2017 ACC/AHA guidelines by estimating early treatment impacts and potential CVD risk reduction.
Methods:
A Markov state-transition simulation model with a 10-year horizon was used to estimate cost-effectiveness, focusing on strengthening target blood pressure. Quality-adjusted life years (QALYs) served as the measure of effectiveness. Cohorts of 10,000 individuals representing South Koreans in their 20s through 80s were compared in scenario analyses from the healthcare system perspective. A 4.5% annual discount rate was applied to costs and effectiveness. Primary outcomes were incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB). The willingness-to-pay (WTP) threshold was < KRW 30,000,000/QALY gained. Probabilistic sensitivity analyses (PSAs) addressed model input parameter uncertainties.
Results:
The base-case analysis showed an ICER value of KRW 1,328,395/QALY gained across all populations. ICER values increased with age, from - KRW 3,138,071/QALY for 20-year-olds to KRW 16,613,013/QALY for individuals over 80. The 60s age group showed the greatest benefit with an incremental QALY gain of 0.46. All scenarios had ICERs below the WTP threshold, with a PSA probability of 98.0% that strengthening blood pressure classification could be cost-effective.
Conclusions:
This economic evaluation found that adopting the 2017 ACC/AHA guidelines may result in early treatment, reduce the potential incidence of CVD events, and be cost-effective across all age groups. The study findings have implications for policymakers deciding whether and when to revise official guidelines regarding target blood pressure levels, considering the impacts on public health and budgetary concerns.
More Related Videos
Related Concept Videos
Pre-Procedural Guidelines for Assessing Blood Pressure
Special considerations while measuring blood pressure
Monitoring Both Arms:
Monitoring BP in both arms during the initial assessment is advisable, as the systolic value may differ by five to ten mm Hg between arms. For subsequent BP assessments, use the arm with the higher reading.
Errors occurring during blood pressure monitoring
Several factors...
Assessment of blood pressure in brachial artery(two-step method)
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension and Regulation of Blood Pressure

